←
AttardLab248 posts
AttardLab avatar✓

AttardLab ✓

@AttardLab

Understanding treatment resistance in prostate cancer @uclcancer. Tweets by Gert & team.

◷ Joined January 2018▧ 35 Photos and videos
Alison Tree 💙 avatar
⟳ AttardLab retweeted
Alison Tree 💙@alison_tree·Jan 16

About time! Good news for those men currently paying out of pocket for Abiraterone and great news for all men who will benefit in future. Well done @ProstateUK for your relentless campaigning to right this wrong.

Post attachment
Advanced Prostate Cancer Consensus Conference avatar
⟳ AttardLab retweeted
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano·25 Sep 2025

🚨 Big News from #APCCC26 🚨 APCCC is opening a Call for Abstracts, creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer! Full details & submission 👉 apccc.org 📅 Key Dates: 🔹 Submission opens: 1 Sept 2025 🔹 Deadline: 14 Nov 2025, 23:59 CET 🔹 Notifications: 19 Dec 2025 ✅ Complimentary registration for presenting authors. ✅ Travel grants available for LMIC investigators. ✅ Selected abstracts will be presented as posters in Lugano (30 Apr–1 May 2026). Categories: Advanced prostate cancer Side effects & QoL/PROs Global access to therapies @Silke_Gillessen & @AOmlin @OncoAlert 🚨 @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrun @DrChoueiri @tompowles1 @brian_rini Ping @nataliagandur @bavilima @yekeduz_emre

0:20
Oscar Tahuahua avatar
⟳ AttardLab retweeted
Oscar Tahuahua@drtahuahua·19 Oct 2025

CAPItello-281 In de novo PTEN-deficient mHSPC (poor prognosis), capivasertib + abiraterone ↑ rPFS vs pbo + abiraterone (33.2 vs 25.7 mo; HR 0.81; P=0.034), OS immature. ↑ PTEN loss correlated with ↑ benefit; POTENTIAL for now With Amplitude trial paving the way, NGS is key in mHSPC How should we integrate this combo when triplet is already available? @OncoAlert @myESMO #ESMO25

Post attachmentPost attachmentPost attachmentPost attachment
AttardLab avatar
AttardLab@AttardLab·19 Oct 2025

EnzaRad P3 trial confirms boundary of patient benefit sits somewhere between STAMPEDE ultra HR and NCCN HR. Working together we will use BM to define this #ESMO25

AttardLab avatar
AttardLab@AttardLab·18 Oct 2025

STAMPEDE update at #ESMO25today at noon. Landmark analysis of 7,129 pts shows PSA ≤0.2 ng/mL by 6–12 weeks strongly predicts OS in HSPC. Prognostic value modified by metastatic volume & nodal status. Abiraterone ± enzalutamide delivers deepest PSA responses & best survival.

Tom Powles avatar
⟳ AttardLab retweeted
Tom Powles@tompowles1·17 Oct 2025

ALBAN #ESMO25 (atezolizumab/BCG vs BCG in MIBC) @Annals_Oncology did not ⬆️ EFS (HR0.97) unlike sasalimab & durvalumab in a similar setting. The drugs seem similar in metastatic UC so was it trial design making it different from other ICIs? EFS was defined differently.

Post attachmentPost attachmentPost attachment
AttardLab avatar
AttardLab@AttardLab·13 Oct 2025

🧪Sequential liquid biopsies reveal ctDNA features and dynamics linked to survival & resistance in advanced #ProstateCancer patients treated with cabazitaxel.
🧬 cell cycle gene amplification associates with taxane resistance 🤝Results from an international collaborative effort